HomeACADEMIA
ACADEMIA

At Least 20% of Patients Taking Xeljanz against Guidelines: Interim Analysis of PMS
(Apr.26.2016)

Over 20% of patients prescribed the oral rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib) did not meet the requirements specified in relevant guidelines, an interim analysis of post-marketing surveillance (PMS) has revealed ...
(LOG IN FOR FULL STORY)

News Calendar